- Company has developed and licensed novel drug delivery systems and products for over 15 years
- With 14 patents, Skinvisible has proven efficacy and global reach
- Proposed merger may transform non-opioid pain market
At the cutting edge of innovative drug delivery technology since 1999, Skinvisible, Inc. (OTCQB: SKVI), in a recently announced Letter of Intent of a proposed merger with Quoin Pharmaceuticals, is now expanding its horizons into the global pain management therapeutics market. The pain management therapeutics market is projected to expand at a 3.7 percent CAGR and exceed $83 billion in the United States by 2024 (http://ibn.fm/1wGbq). Skinvisible, through wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., has already developed, licensed and sold multiple dermatology and health care products, as well as various medical treatments, using its patented Invisicare® technology. The proposed merger with Quoin Pharmaceuticals (http://ibn.fm/dJWLM) would combine Skinvisible’s patented and proven novel drug delivery technologies that enhance the delivery of various active ingredients with Quion’s strong pharmaceutical background in post-surgical pain and promising approach to PTSD treatment.
Skinvisible has a long, successful history developing and licensing Invisicare®, its patented polymer technology. Enhancing how drugs are delivered on, in, or through the skin, Invisicare® has proven efficacy in a wide range of dermatology and health care products, including products to treat acne, skin cancers, eczema, fungal infections, inflammation, warts and dermatitis. Broad applications extend to sunscreens, anti-aging products, alcohol-free hand sanitizing lotions, pre-surgical preparations and, now, with a Quoin merger, the enhanced delivery of important non-opioid pain management medications.
With a focus on a lucrative licensing model and over 40 products developed in topical dermatology, Skinvisible has already achieved impressive market traction. The company offers a premium line of scientifically formulated, highly effective skincare products powered by its Invisicare® technology and has revolutionized the topical sunscreen market with Skinbrella®, a patented broad-spectrum 80-minute water-resistant sunscreen that meets or exceeds all FDA requirements.
Last year, Skinvisible completed its first international sale of alcohol-free DermSafe® hand sanitizers in China. DermSafe® utilizes a unique formulation that provides a long-lasting protective barrier that binds to the skin for hours and reduces the spread of germs between people and hard surfaces. In September 2017, the company signed a breakthrough exclusive license agreement with Canopy Growth (TSX: WEED) for two distinct cannabis- and hemp-based topical product lines aimed at enhancing penetration of topically used cannabis products.
With 14 patents granted surrounding its novel drug delivery systems and products, it’s little wonder that Quoin Pharmaceuticals looks to merge with Skinvisible. Delivering enhanced and effective non-opioid pain relief is the current Holy Grail of pharmacology, and Skinvisible’s contribution to what may become transformative pain management delivery shouldn’t be underestimated.
For more information, visit the company’s website at www.Skinvisible.com
Let us hear your thoughts: Skinvisible, Inc. Message Board
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.